Abstract 408P
Background
Lung cancer is the leading cause of cancer-related mortality worldwide. Chemotherapy and EGFR TKI combinations may be possible treatment options for patients with NSCLC and activating EGFR mutations. Many clinical trials have shown the potential benefits of these combinations.The addition of chemotherapy to first - and second - generation tyrosine kinase inhibitors significantly improved PFS compared with tyrosine kinase inhibitors monotherapy in treatment- naive patients with EGFR-mutated advanced NSCLC.We undertook the open prospective non-randomized multi -center study in a similar patient population.
Methods
We recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were administrated at days 71-113. Thereafter, gefitinib was re-started on day 135 and continued until disease progression. The primary endpoint was progressive free survival (PFS) time.
Results
From May 2016 to May 2018, 54 patients with advanced (IIIB / IV stages) NSCLC, with activating mutation of the EGFR gene in exon 19 or 21, were included in the study. The objective response rate (ORR) was 55,5%. Serious adverse events were reported by 4 (7,4%) of 54 patients. 2-year PFS in all patients group included in the study at the time of the preliminary analysis was 38.9%, median PFS was 20,0 months (16.0–23,9CI 95%). Median overall survival was not reached.
Conclusions
Integrated chemotherapy with first - and second - generation tyrosine kinase inhibitors is a viable first-line option for patients with non-small-cell lung cancer with EGFR mutation-positive disease, wich can help overcome acquired resistance to tyrosine kinase inhibitors. Tretment benefit of integrated chemotherapy compared with monotherapy of tyrosine kinase inhibitors 1-2 generations is obvious when comparing the results of our study with the data of randomized trials devoted to this problem.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. Laktionov.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session